Metsera’s drug shows potential to be a once-monthly obesity med

The latest stories trending on MedCity News.

Editor's Pick

Top Story Metsera's Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med Novo Nordisk, AbbVie, and Roche each have weekly injectable drug candidates designed to bind to and activate the amylin receptor to trigger weight loss. Metsera's contender, MET-233i, is designed with technology that enables longer dosing intervals and the company is proceeding with development of this engineered peptide as a monotherapy and as part of a drug combination. Sponsored Boost Call Center Efficiency with 25% Call Deflection Presented by Relatient Patients expect the same seamless, on-demand experiences from healthcare that they get in other parts of life. Not only does AI-enabled access meet patient expectations, it improves staff efficiency. Organizations have seen 25% call deflection by leveraging Voice AI agents and digital access points. Explore how digital strategies are transforming patient access, and how your organization can lead the shift to more modern, scalable call center operations. Learn More.   Call for Speakers: INVEST Digital Health 2025 Are you shaping the future of digital health and AI? We invite thought leaders, innovators, and industry experts to apply to speak at INVEST Digital Health 2025. This is your opportunity to share your insights, experiences, and vision with a dynamic audience of healthcare leaders, investors, and entrepreneurs. Apply Now

Featured News

Investors Share How Early Stage Healthcare Startups Are Using AI [Sponsored] Business banking provider* Mercury sponsored a webinar discussing early stage investment topics with venture capitalists such as grant funding secrets, capital valuation, the role of AI in life sciences, and more. Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted FDA approval of Merck's RSV antibody drug, Enflonsia, makes it a direct competitor to Sanofi's Beyfortus. The new Merck product is expected to be discussed by the CDC's Advisory Committee on Immunization Practices; ACIP will have an entirely new roster at its next meeting after all 17 sitting members were dismissed by Health and Human Services Secretary Robert F. Kennedy Jr. GoodRx Unveils Cost-Plus Model for Independent Pharmacies GoodRx launched Community Link, a new cost-plus pricing program that allows independent pharmacies to contract directly with GoodRx. In Axing mRNA Contract, Trump Delivers Another Blow to US Biosecurity, Former Officials Say The Trump administration has cancelled $766 million in contracts to develop mRNA vaccines against potential pandemic flu viruses. In addition, since President Donald Trump took office, at least half of the security council's staff have been laid off or left. This is dangerous say former health security officials. Whole Eye Transplantation is No Longer Just Science Fiction The technologies and techniques developed for eye transplantation and nerve regeneration may have significant translational potential for other biomedical needs including: spinal cord injury, central nervous system regeneration, retinal cell and tissue transplantation, and other forms of organ and tissue transplantation.  The Hidden Frontline of Public Health: How EMS Data Is Powering a New Era of Syndromic Surveillance  EMS data is often the earliest signal of a looming public health crisis. By tapping into it in real time, agencies can detect overdose spikes, respiratory surges, or behavioral health trends days before traditional systems catch up.

Video   How Might the GOP's Budget Plan Affect Hospitals' Margins? The Trump administration's flagship budget package, which is making its way through Congress, includes the biggest Medicaid funding cuts ever proposed in the history of the program. Experts believe this bill would lead to unsustainable revenue losses for providers. An increase in uninsured patients would lead to more uncompensated care — which could drive up hospitals' costs during a time when their expenses are already climbing steadily. Experts also think the legislation could result in higher premiums for commercially insured patients. Hospitals factor in things like bad debt and unpaid patient bills when they're negotiating rates with insurers — and this often ends up driving up healthcare costs for the average consumer.

Sponsored Your Guide to the Best Vein Clinics in Orlando Presented by Central Florida Vein and Vascular Center Your varicose or spider veins may indicate an underlying problem, so finding the right vein specialist is crucial. Discover the best vein clinics in Orlando. Learn More

Resources

MedCity FemFwd: Investment Trends In Women's Health In this episode, we're joined by Margaret Malone, principal of Flare Capital Partners. She discusses the investment trends she's following in the women's health space and advice she has for startups. Watch Now

MedCity News • PO Box 901 • New York, NY unsubscribe